Didrogestrel tablets are an oral progestogen that allows the endometrium to enter a fully secretory phase, thereby preventing estrogen-induced endometrial hyperplasia and the risk of cancer; didrogestrel has no estrogenic, androgenic, or adrenocorticotropic effects; didrogestrel is not thermogenic and has no effect on lipid metabolism. The following adverse reactions have been reported in clinical trials and/or marketing and sale use of didrogestrel: other adverse reactions from post-marketing that are associated with didrogestrel and occur with unknown frequency: benign, malignant and unspecified tumors (including cysts and polyps), progesterone-dependent increase in tumor size (e.g., meningioma); psychiatric disorders: depressed mood, nervousness; other: vomiting, altered libido. Reproductive and breast disorders, breast swelling; adverse effects associated with estrogen-progestin therapy: breast cancer, endometrial hyperplasia, endometrial cancer, sex hormone-dependent tumors (malignant/benign), venous thrombosis, myocardial infarction, cardiovascular accidents. There have been no reports of sequelae from overdose of didrogestrel. The toxicity of dydrogesterone is minimal, and overdose may result in nausea, vomiting, drowsiness, and dizziness. There is limited information available on overdose in humans. Dydrogesterone is well tolerated after oral administration (maximum daily human dose of 360 mg). There is no specific antidote and treatment should be symptomatic. The above information is also used for drug overdose in children.